AbbVie Eyes $10.9 Billion Biotech Acquisition to Add Experimental Eczema Drug

AbbVie is reportedly pursuing the acquisition of a biotech company for $10.9 billion in cash, with the deal centered on an experimental atopic dermatitis treatment, according to a Financial Times report. The transaction, if completed, would give AbbVie a promising eczema drug still navigating clinical development. No official confirmation has been issued by AbbVie.

$10.9 Billion, All Cash

The Financial Times reported the deal at $10.9 billion in cash — a structure that removes uncertainty for the target's shareholders by decoupling any payout from AbbVie's stock performance in the period between agreement and closing. Transactions of this magnitude in pharmaceutical M&A are closely watched as a signal of how aggressively established drug companies will compete for development-stage pipeline assets.

The Financial Times did not name the biotech company or the experimental drug at the center of the deal. What the report does establish is that AbbVie is willing to deploy nearly $11 billion in cash for access to a single development-stage compound — a figure that reflects the commercial expectations the company has placed on the atopic dermatitis drug in question.

The Atopic Dermatitis Angle

Atopic dermatitis — the clinical designation for the most common form of eczema — is a chronic inflammatory skin condition that has drawn sustained pharmaceutical investment. The category has become increasingly competitive as companies pursue treatments that could serve patients inadequately addressed by existing therapies.

By acquiring a biotech with a drug positioned in this space, AbbVie would extend its reach in the immunology and dermatology categories. The willingness to commit $10.9 billion entirely in cash, before the experimental compound has cleared regulatory review, signals that AbbVie views the drug as a meaningful long-term portfolio asset.

What Comes Next

The deal remains at the reported stage, with no formal announcement from AbbVie. Key questions outstanding include the identity of the biotech target, the clinical development stage of the experimental drug, and any regulatory review requirements tied to a transaction of this scale. An official announcement, when issued, would be expected to address closing conditions and financing details.